

ASX Release

NOVITA'S TALI DETECT TO BE USED TO ASSESS ATTENTION DEFICIT ISSUES IN VICTORIAN PUBLIC SCHOOL CHILDREN

Novita Healthcare Limited (ASX: NHL) (“**Novita**” or the “**Company**”) is pleased to announce it has agreed with the Victorian Education Department for Tali Detect (Novita’s new digital assessment tool for lack of attention in early childhood) to be delivered to children aged 5,6 and 7 in the Victorian public education system commencing term 3, 2019.

Approximately 300,000 children begin school each year in Australia with 81,000 of those entering the Victorian school system. The 5, 6 and 7-year-old range represent approximately 200,000 children in the Victorian education system¹.

Tali Detect has been the result of our collaboration with Monash University and partners via an Australian Federal Government Cooperative Research Centre – Project (CRC-P) to provide an evidence based, non-invasive digital tool to assess children at the critical learning ages to determine if further intervention is required to treat attention deficit issues.

The results of the Tali Detect clinical trials are set to be released by September. However, there is a recognised significant benefit of deploying Tali Detect into the Victorian education system prior to release of the trial results and its’ official market launch later this year. Novita looks forward to informing shareholders of the clinical trial results.

Tali Detect will be the frontline digital assessment tool that compliments Tali Train, Novita’s scientifically validated, regulatory cleared by the TGA (Therapeutic Goods Administration, Australia) and the FDA (Food and Drug Administration, USA), in market digital attention training program (www.talihealth.com).

Managing Director Comment

Novita Managing Director Glenn Smith said: “This is a significant step forward for Novita as schools will have the ability to assess **all** children entering the public-school system for potential attention deficits. This will allow teachers and parents the ability to determine whether appropriate further intervention such as our world leading attention training program Tali Train, should be provided to children in need. This will provide Novita with direct access to tens of thousands of Australian homes for the first time.”

Children from the Victorian public-school system participated in the clinical trial program for Tali Detect and this agreement between Novita and the Victorian Education Department is a direct result of that clinical trial program (results of the clinical trial program are set to be released by September). Novita will work with the Victorian Education Department on a coordinated communication and rollout strategy. The program will be delivered cost free for an initial 12-month period. During this period Novita will initiate further discussions on a long-term pricing and delivery model for Tali Detect in the Victorian education system.

¹ Source: ABS, Cat. No. 4221.0, Schools, Australia, 2013

Any child identified via Tali Detect as requiring intervention will be offered Novita's attention training program Tali Train at the standard list price for schools. 1 in 20 children in Australia have ADHD² and 1 in 50 have Autism Spectrum Disorder³. Novita expects those rates to be represented in the Victorian public-school system meaning tens of thousands of children may be suitable to use Tali Train potentially leading to a material rise in the use and sales of the program.

Tali Detect is due for wider release in the 2019/2020 financial year and the Company will continue to work with other State education departments and the Federal government in relation to its implementation in the education system.

ABOUT NOVITA

Novita Healthcare Limited (ASX: NHL) is a leading early childhood technology business targeting ATTENTION in children through its breakthrough Tali platform. Tali combines evidence based proprietary algorithms inside a game-based program to assess (Tali Detect) and strengthen (Tali Train) core attention in early childhood (www.talihealth.com).

CONTACT

Glenn Smith

Managing Director

Novita Healthcare Ltd

p: 1300 082 013

e: novita@novitahealthcare.com.au

Sue MacLeman

Chair

Novita Healthcare Ltd

p: 1300 082 013

e: smacleman@novitahealthcare.com.au

² Source: <https://www.healthdirect.gov.au/adhd-in-children>

³ Source: <https://www.autismspectrum.org.au/news/autism-prevalence-rate-up-by-an-estimated-40-to-1-in-70-people-11-07-2018>